These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 28506516)
1. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Klein NP; Bartlett J; Fireman B; Aukes L; Buck PO; Krishnarajah G; Baxter R Vaccine; 2017 Jun; 35(26):3395-3400. PubMed ID: 28506516 [TBL] [Abstract][Full Text] [Related]
2. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. Misegades LK; Winter K; Harriman K; Talarico J; Messonnier NE; Clark TA; Martin SW JAMA; 2012 Nov; 308(20):2126-32. PubMed ID: 23188029 [TBL] [Abstract][Full Text] [Related]
3. Waning protection after fifth dose of acellular pertussis vaccine in children. Klein NP; Bartlett J; Rowhani-Rahbar A; Fireman B; Baxter R N Engl J Med; 2012 Sep; 367(11):1012-9. PubMed ID: 22970945 [TBL] [Abstract][Full Text] [Related]
4. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR; Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582 [TBL] [Abstract][Full Text] [Related]
5. Waning Tdap Effectiveness in Adolescents. Klein NP; Bartlett J; Fireman B; Baxter R Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667 [TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A; Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Klein NP; Bartlett J; Fireman B; Rowhani-Rahbar A; Baxter R Pediatrics; 2013 Jun; 131(6):e1716-22. PubMed ID: 23690518 [TBL] [Abstract][Full Text] [Related]
8. Duration of protection after first dose of acellular pertussis vaccine in infants. Quinn HE; Snelling TL; Macartney KK; McIntyre PB Pediatrics; 2014 Mar; 133(3):e513-9. PubMed ID: 24515514 [TBL] [Abstract][Full Text] [Related]
9. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection. Matheson AJ; Goa KL Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466 [TBL] [Abstract][Full Text] [Related]
10. Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. Domenech de Cellès M; Rohani P; King AA JAMA Pediatr; 2019 Jun; 173(6):588-594. PubMed ID: 31009031 [TBL] [Abstract][Full Text] [Related]
11. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. Glanz JM; Narwaney KJ; Newcomer SR; Daley MF; Hambidge SJ; Rowhani-Rahbar A; Lee GM; Nelson JC; Naleway AL; Nordin JD; Lugg MM; Weintraub ES JAMA Pediatr; 2013 Nov; 167(11):1060-4. PubMed ID: 24019039 [TBL] [Abstract][Full Text] [Related]
12. Waning immunity to pertussis following 5 doses of DTaP. Tartof SY; Lewis M; Kenyon C; White K; Osborn A; Liko J; Zell E; Martin S; Messonnier NE; Clark TA; Skoff TH Pediatrics; 2013 Apr; 131(4):e1047-52. PubMed ID: 23478868 [TBL] [Abstract][Full Text] [Related]
13. Acellular Pertussis Vaccine Effectiveness Over Time. Zerbo O; Bartlett J; Goddard K; Fireman B; Lewis E; Klein NP Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31182549 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Baxter R; Bartlett J; Fireman B; Lewis E; Klein NP Pediatrics; 2017 May; 139(5):. PubMed ID: 28557752 [TBL] [Abstract][Full Text] [Related]
15. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143 [TBL] [Abstract][Full Text] [Related]
16. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. America Academy of Pediatrics Commitee on Infectious Diseases Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131 [TBL] [Abstract][Full Text] [Related]
17. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV; MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217 [TBL] [Abstract][Full Text] [Related]
18. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395 [TBL] [Abstract][Full Text] [Related]
20. Duration of pertussis immunity after DTaP immunization: a meta-analysis. McGirr A; Fisman DN Pediatrics; 2015 Feb; 135(2):331-43. PubMed ID: 25560446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]